Latest Conference Articles

At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.

The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.

At AAO 2024, Khanani discussed data showing a 97% reduction in annualized injection needs at 9 months with RGX-314 gene therapy.

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

This overview highlights our upcoming conference coverage at the Fall Clinical Dermatology Conference in Las Vegas.

Decreasing Vitamin A dimerization could be a potential mechanism to treat geographic atrophy, according to results from the two-year SAGA study at AAO 2024.

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

At AAO 2024, Pearlman discusses how an innovative oral approach may provide an alternative pathway to existing treatments for DME.

Endophthalmitis incidence remained similar between face masking and non-face masking groups during anti-VEGF treatment.

TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.

The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

At AAO 2024, Schneider explains the pivotal trial outcomes of AI-based home OCT, compared with standard in-office OCT scans.

At AAO 2024, Cunningham describes the clinical response and safety of faricimab (Vabysmo) in underrepresented populations with diabetic macular edema.

A history of anti-VEGF injections for retinal conditions may increase the incidence of complications after cataract surgery.

OCU400 gene therapy remained safe and tolerable across different mutation and dose cohorts in retinitis pigmentosa and Leber congenital amaurosis.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

Bau explains the challenges of using MELD to determine liver transplant referrals and other complexities of the evaluation process.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.